Last Updated: June 10, 2026

ELTROMBOPAG Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Eltrombopag patents expire, and when can generic versions of Eltrombopag launch?

Eltrombopag is a drug marketed by Annora Pharma, Aizant, Amneal, Dr Reddys, Hetero Labs Ltd V, Hikma, MSN, Somerset Theraps Llc, and Zydus Pharms. and is included in nine NDAs.

The generic ingredient in ELTROMBOPAG is eltrombopag olamine. There are three drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the eltrombopag olamine profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Eltrombopag

A generic version of ELTROMBOPAG was approved as eltrombopag olamine by ANNORA PHARMA on April 18th, 2024.

  Start Trial

AI Deep Research
Ask!
Questions you can ask:
  • What is the 5 year forecast for ELTROMBOPAG?
  • What are the global sales for ELTROMBOPAG?
  • What is Average Wholesale Price for ELTROMBOPAG?
Summary for ELTROMBOPAG
US Patents:0
Applicants:9
NDAs:9
DailyMed Link:ELTROMBOPAG at DailyMed
Drug patent expirations by year for ELTROMBOPAG
Pharmacology for ELTROMBOPAG
Drug ClassThrombopoietin Receptor Agonist
Mechanism of ActionBreast Cancer Resistance Protein Inhibitors
Organic Anion Transporting Polypeptide 1B1 Inhibitors
Thrombopoietin Receptor Agonists
UGT1A1 Inhibitors
UGT1A3 Inhibitors
UGT1A4 Inhibitors
UGT1A6 Inhibitors
UGT1A9 Inhibitors
UGT2B15 Inhibitors
UGT2B7 Inhibitors
Physiological EffectIncreased Megakaryocyte Maturation
Increased Platelet Production

US Patents and Regulatory Information for ELTROMBOPAG

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Zydus Pharms ELTROMBOPAG OLAMINE eltrombopag olamine TABLET;ORAL 216281-002 Jan 14, 2026 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Somerset Theraps Llc ELTROMBOPAG OLAMINE eltrombopag olamine TABLET;ORAL 219638-002 Jan 14, 2026 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Zydus Pharms ELTROMBOPAG OLAMINE eltrombopag olamine TABLET;ORAL 216281-003 Jan 14, 2026 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Somerset Theraps Llc ELTROMBOPAG OLAMINE eltrombopag olamine TABLET;ORAL 219638-003 Jan 14, 2026 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Annora Pharma ELTROMBOPAG OLAMINE eltrombopag olamine FOR SUSPENSION;ORAL 216620-001 Apr 18, 2024 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Hetero Labs Ltd V ELTROMBOPAG OLAMINE eltrombopag olamine TABLET;ORAL 206788-004 Jan 17, 2025 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Subscribe to access the full database, or Start Trial

DrugChatter Q&A for ELTROMBOPAG
Eltrombopag patent expiry date?

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
 NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links